ProCE Banner Activity

The Expanding Evidence Base for Oral SERDs and Other ER-Targeting Agents

Slideset

Download slides with the most recent clinical trial data on optimizing oral SERDs therapy for patients with HR+/HER2- breast cancer.

Released: May 30, 2024

Expiration: May 29, 2025

Share

Faculty

Virginia Kaklamani

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly